Evaxion Biotech A/S announced that it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Rønø has more than 15 years' experience in biopharmaceutical drug discovery, both in academia and industry. Prior to joining Evaxion, Dr. Rønø served as a specialist, team leader and project manager at Novo Nordisk A/S, where she led early drug discovery projects, evaluated in-licensing opportunities, and supported drug development projects with pre-clinical and biomarker expertise.